



Statistical Analysis Plan

Version 3.1

Date: 29 October 2021

Aligned with protocol version: 18.1, 29 October 2021

IRAS no: 281712
REC ref: EE/20/0101
ISRCTN: 50189673
EudraCT: 2020-001113-21

Nuffield Department of
POPULATION HEALTH



Table of Contents

Table of Contents.....	2
Abbreviations.....	6
List of authors and reviewers (up to and including SAP version 1.1)	7
List of authors and reviewers (version 2.0 onwards)	7
Roles and responsibilities	8
1 Introduction	9
2 Background information	10
2.1 Rationale	10
2.2 Objectives of the trial	10
2.2.1 Primary objective	10
2.2.2 Secondary objectives	10
2.3 Trial design	10
2.4 Eligibility	10
2.4.1 Inclusion criteria.....	10
2.4.2 Exclusion criteria	10
2.5 Treatments	10
2.5.1 Main randomisation part A:.....	11
2.5.2 Main randomisation part B:.....	11
2.5.3 Main randomisation part C:.....	12
2.5.4 Main randomisation part D:	12
2.5.5 Main randomisation part E:	12
2.5.6 Second randomisation for adults with progressive COVID-19	12
2.6 Definitions of primary and secondary outcomes.....	13
2.6.1 Primary outcome	13
2.6.2 Secondary clinical outcomes.....	13
2.6.3 Subsidiary clinical outcomes	13
2.6.4 Safety outcomes	13
2.6.5 Detailed derivation of outcomes	14
2.9 Randomisation	14
2.9.1 Main randomisation part A.....	14
2.9.2 Main randomisation part B.....	15
2.9.3 Main randomisation part C.....	15
2.9.4 Main randomisation part D.....	15
2.9.5 Main randomisation part E	15

2.9.6	Second randomisation for adults with progressive COVID-19	16
2.10	Blinding	16
2.11	Data collection schedule.....	16
2.12	Data monitoring.....	17
2.13	Trial reporting	17
3	Analysis populations	17
3.1	Population definitions	17
4	Descriptive analyses.....	17
4.1	Participant throughput.....	17
4.2	Baseline comparability of randomised groups	17
4.2.1	Main randomisation (parts A, B and C).....	18
4.2.2	Second randomisation	18
4.3	Completeness of follow-up	18
4.4	Adherence to treatment	19
5	Comparative analyses	19
5.1	Main randomisation part A	19
5.1.1	Primary outcome	19
5.1.2	Secondary outcomes.....	19
5.1.3	Time to discharge alive from hospital.....	20
5.1.4	Use of invasive mechanical ventilation (including ECMO) or death.....	20
5.1.5	Subsidiary clinical outcomes	20
5.1.6	Use of ventilation (overall and by type)	20
5.1.7	Duration of invasive mechanical ventilation (time to successful cessation of invasive mechanical ventilation).....	20
5.1.8	Use of renal dialysis or haemofiltration.....	20
5.1.9	Thrombotic event	21
5.2	Main randomisation part B	21
5.3	Main randomisation part C	21
5.4	Main randomisation part D	21
5.5	Main randomisation part E	21
5.6	Second randomisation	21
5.7	Pre-specified subgroup analyses.....	22
5.8	Sensitivity analyses.....	22
5.9	Other exploratory analyses	22
5.10	Adjustment for baseline characteristics.....	23
5.11	Significance levels and adjustment of p-values for multiplicity	23

5.12	Statistical software employed	23
5.13	Data standards and coding terminology	23
6	Safety data	23
6.1	Cause-specific mortality	24
6.2	Major cardiac arrhythmia.....	24
6.3	Major bleeding	24
6.4	Early safety of antibody-based therapy	24
7	Additional POST-HOC exploratory analysis.....	24
8	Differences from protocol	24
9	EARLY PHASE ASSESSMENTS.....	26
9.1	Definitions of clinical outcomes	26
9.1.1	Primary outcome	26
9.1.2	Secondary clinical outcomes.....	26
9.1.3	Subsidiary clinical outcomes	26
9.1.4	Safety outcomes	26
9.2	Baseline comparability of randomised groups	26
9.3	Comparative analysis	26
9.3.1	Primary outcome	26
9.3.2.2	Improvement in clinical status at day 10	27
9.3.2.3	Average WHO ordinal scale on days 3, 7, and 10	Error! Bookmark not defined.
9.3.2.4	Study average blood C-reactive protein	27
9.3.2.5	S/F ₉₄ ratio at days 3 and 10	27
9.3.3	Safety outcomes	27
10	6-MONTH ASSESSMENTS.....	28
10.1	Trial outcomes	28
10.1.1	Changes to definition of clinical outcomes.....	28
10.1.1.1	Use of ventilation	28
10.1.1.2	Use of renal dialysis or haemofiltration	28
10.1.2	Additional exploratory analyses	28
10.1.2.1	Readmission to hospital	28
10.1.2.2	<i>Total duration of critical and hospital in-patient care</i>	29
10.1.3	Outcomes which not be assessed at 6 months	Error! Bookmark not defined.
10.2	Censoring and analysis	29
11	References	30
11.1	Trial documents	30

11.2	Other references	30
12	APPENDIX A: Analyses of REGN-COV2	31
12.1	Background & rationale.....	31
12.2	Analytical plan	31
12.3	References	32
13	Approval.....	34
14	Document history	35

Abbreviations

ADaM	Analysis Data Model
AE	Adverse event
CDISC	The Clinical Data Interchange Standards Consortium
CI	Confidence interval
COVID	Coronavirus-induced disease
CPAP	Continuous Positive Airway Pressure
CRP	C-reactive protein
DMC	Data Monitoring Committee
ECMO	Extra Corporeal Membrane Oxygenation
eCRF	Electronic case report form
ICD	International Classification of Diseases
ICNARC	Intensive Care National Audit and Research Centre
ITT	Intention to treat
MedDRA	Medical Dictionary for Regulatory Activities
OPCS-4	National Health Service OPCS Classification of Interventions and Procedures version 4
SARS	Severe acute respiratory syndrome
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
S/F ₉₄ ratio	Ratio of peripheral oxygen saturation to fractional inspired oxygen concentration when peripheral oxygen saturation at or below 94%
SSAR	Suspected serious adverse reaction
SUSAR	Suspected unexpected serious adverse reaction
TSC	Trial Steering Committee

List of authors and reviewers (up to and including SAP version 1.1)

Authors

Dr Louise Linsell, Lead Trial Statistician, Nuffield Department of Population Health (NDPH), University of Oxford

Jennifer Bell, Trial Statistician, NDPH, University of Oxford

Reviewers

Professor Jonathan Emberson, Data Monitoring Committee (DMC) Statistician, NDPH, University of Oxford (prior to unblinded interim analysis of trial outcomes)

Professor Richard Haynes, Clinical Coordinator, NDPH, University of Oxford

Professor Peter Horby, Chief Investigator (CI), Nuffield Department of Medicine, University of Oxford

Professor Thomas Jaki, TSC Member, Department of Mathematics and Statistics, Lancaster University

Associate Professor Edmund Juszczak, TSC Member, NDPH, University of Oxford (until 6 July 2020)

Professor Martin Landray, Deputy CI, NDPH, University of Oxford

Professor Alan Montgomery, TSC Member, Nottingham Clinical Trials Unit, University of Nottingham

Dr Natalie Staplin, DMC Statistician, NDPH, University of Oxford (prior to unblinded interim analysis of trial outcomes)

List of authors and reviewers (version 2.0 onwards)

Professor Edmund Juszczak, TSC Member (University of Nottingham from 6 July 2020)

Professor Alan Montgomery (University of Nottingham), TSC Member

Professor Thomas Jaki (University of Cambridge) co-investigator and TSC Member

Enti Spata, Trial Statistician, NDPH, University of Oxford

Professor Richard Haynes, Clinical Coordinator, NDPH, University of Oxford

Professor Martin Landray, Deputy CI, NDPH, University of Oxford

Professor Peter Horby, CI, Nuffield Department of Medicine, University of Oxford

Roles and responsibilities

Trial Statisticians

Until 30th September 2020: Dr Louise Linsell and Jennifer Bell (NDPH, University of Oxford)

Role: To develop the statistical analysis plan (blinded to trial allocation) and conduct the final comparative analyses for Lopinavir-Ritonavir, Corticosteroid (dexamethasone) and Hydroxychloroquine (main randomisation part A).

From 1st October 2020: Enti Spata (NDPH, University of Oxford)

Role: To develop the statistical analysis plan (blinded to trial allocation) and conduct the final comparative analyses for all other treatment arms.

Data Monitoring Committee (DMC) Statisticians

Professor Jonathan Emberson and Dr Natalie Staplin (NDPH, University of Oxford)

Role: To conduct regular interim analyses for the DMC. Contribution restricted up until unblinded to trial allocation.

Statisticians on the Trial Steering Committee (TSC)

Professor Edmund Juszczak (University of Nottingham), Professor Alan Montgomery (University of Nottingham), and Professor Thomas Jaki (University of Cambridge)

Role: Major organisational and policy decisions, and scientific advice; blinded to treatment allocation.

Trial IT systems & Programmers

Andy King, David Murray, Richard Welsh (NDPH, University of Oxford)

Role: To generate and prepare reports monitoring the randomisation schedule. To supply data snapshots for interim and final analysis. Responsibility for randomisation system, clinical databases and related activities.

Bob Goodenough (NDPH, University of Oxford)

Role: Validation of IT systems

Dr Will Stevens, Karl Wallendszus (NDPH, University of Oxford)

Role: To produce analysis-ready datasets according to CDISC standards.

1 INTRODUCTION

This document details the proposed presentation and analysis for the main paper(s) reporting results from the multicentre randomised controlled trial RECOVERY (ISRCTN50189673) to investigate multiple treatments on major outcomes in inpatients for COVID-19 (clinically suspected or laboratory confirmed).

The results reported in these papers will follow the strategy set out here, which adheres to the guidelines for the content of a statistical analysis plan (SAP).¹ Any subsequent analyses of a more exploratory nature will not be bound by this strategy.

Suggestions for subsequent analyses by oversight committees, journal editors or referees, will be considered carefully in line with the principles of this analysis plan.

Any deviations from the statistical analysis plan will be described and justified in the final report. The analysis will be carried out by identified, appropriately qualified and experienced statisticians, who will ensure the integrity of the data during their processing.

This SAP is based on multiple versions of the protocol. All regulatory documents can be found in the RECOVERY trial directory: <https://www.recoverytrial.net/for-site-staff/site-set-up-1/regulatory-documents>.

SAP versions 1.0 & 1.1 applied to the first three principal comparisons (hydroxychloroquine, dexamethasone, and lopinavir-ritonavir versus no additional treatment respectively), for which data matured in the first UK wave of the pandemic. However, due to its later introduction, enrolment of patients in the azithromycin arm was much slower. Over time, factorial randomisations and a second randomisation have been added, introducing new treatment arms including convalescent plasma, tocilizumab, synthetic neutralizing antibodies, and aspirin. Version 2.0 of the SAP was produced in response to these changes, combined with the fact that use of corticosteroids (one of the original treatment arms) is now the usual standard of care for many patients.

SAP version 3.0 now includes the following revisions:

- **REGN-COV2:** Specification of analysis method (see appendix).
- **Early phase assessments:** Additional analyses for treatments undergoing early phase assessment (introduced in protocol version 14.0; modified in SAP version 3.1); see section 9.
- **6 month follow-up:** Analyses based on information available up to 6 months after randomisation (modified in SAP version 3.1); see section 10.

The primary outcome for children will be the duration of hospitalisation (and death is an extremely rare event). The analyses of data from children will be specified in a separate Statistical Analysis Plan.

2 BACKGROUND INFORMATION

2.1 Rationale

In early 2020, as the protocol was being developed, there were no approved treatments for COVID-19. The aim of the trial is to provide reliable evidence on the efficacy of candidate therapies (including re-purposed and novel drugs) for suspected or confirmed COVID-19 infection on major outcomes in hospitalised adult patients receiving standard care.

2.2 Objectives of the trial

2.2.1 *Primary objective*

To provide reliable estimates of the effect of study treatments on all-cause mortality within 28 days of the relevant randomisation.

2.2.2 *Secondary objectives*

To investigate the effect of study treatments on the duration of hospital stay and on the combined endpoint of use of invasive mechanical ventilation (including Extra Corporal Membrane Oxygenation [ECMO]) or death.

2.3 Trial design

This is a multi-centre, multi-arm, adaptive, open label, randomised controlled trial with three possible stages of randomisation, as described below. The trial is designed with streamlined processes in order to facilitate rapid large-scale recruitment with minimal data collection.

2.4 Eligibility

2.4.1 *Inclusion criteria*

Patients are eligible for the trial if all of the following are true:

- Hospitalised
- SARS-Cov-2 infection (clinically suspected or laboratory confirmed)
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial.

2.4.2 *Exclusion criteria*

If one or more of the active drug treatments is not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then this fact will be recorded via the web-based form prior to randomisation; random allocation will then be between the remaining arms.

2.5 Treatments

All patients will receive standard management for the participating hospital. The main randomisation will be between the following treatment arms (although not all arms may be

available at any one time). The doses listed are for adults; paediatric dosing is described in the protocol.

2.5.1 *Main randomisation part A:*

- **No additional treatment**
- **Lopinavir 400mg-Ritonavir 100mg** by mouth (or nasogastric tube) every 12 hours for 10 days. [Introduced in protocol version 1.0; **enrolment closed** 29 June 2020]
- **Corticosteroid** in the form of dexamethasone, administered as an oral liquid or intravenous preparation 6 mg once daily for 10 days. In pregnancy, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead. [Introduced in protocol version 1.0; **enrolment closed to adults** 8 June 2020]
- **Hydroxychloroquine** by mouth for 10 days (4 doses in first 24 hours and 1 dose every 12 hours for 9 days). [Introduced in protocol version 2.0; **enrolment closed** 5 June 2020]
- **Azithromycin 500mg** by mouth (or nasogastric tube) or intravenously once daily for a total of 10 days. [Introduced in protocol version 3.0; **enrolment closed** 27 November 2020]
- **Colchicine** by mouth for 10 days (1.5 mg in first 12 hours then 0.5 mg twice daily). [Introduced in protocol version 12.0; **enrolment closed** 5 March 2021.]
- **Dimethyl fumarate** 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total). [Introduced in protocol version 14.0; enrolment ongoing.] **Undergoing Early Phase Assessment**

2.5.2 *Main randomisation part B:*

In a factorial design, eligible patients may be randomised to the arms below. The doses listed are for adults; paediatric dosing is described in the protocol.

- **No additional treatment**
- **Convalescent plasma** Single unit of ABO compatible convalescent plasma (275mls \pm 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12-hour interval between 1st and 2nd units). ABO identical plasma is preferred if available. The second transfusion should not be given if patient has a suspected serious adverse reaction during or after the first transfusion. [Introduced in protocol version 6.0; **enrolment closed** 15 January 2021]
- **Synthetic neutralising antibodies** (REGN-COV2; adults and children aged ≥ 12 years only - children who weigh < 40 kg will also not be eligible for this treatment). A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes \pm 15 minutes as soon as possible after randomisation. [Introduced in protocol version 9.1; **enrolment closed** 22 May 2021]

2.5.3 *Main randomisation part C:*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children are excluded from this comparison.

- **No additional treatment**
- **Aspirin** 150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge. [Introduced in protocol version 10.1; **enrolment closed** 21 March 2021]

2.5.4 *Main randomisation part D:*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children <2 years old or with PIMS-TS are excluded from this comparison.

- **No additional treatment**
- **Baricitinib** 4 mg by mouth (or nasogastric tube) once daily for 10 days. [Introduced in protocol version 13.0; **enrolment ongoing**]

2.5.5 *Main randomisation part E:*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **High-dose corticosteroids** dexamethasone 20 mg once daily for 5 days, followed by dexamethasone 10 mg once daily for 5 days. [Introduced in protocol version 13.0; **enrolment ongoing**]

2.5.6 *Main randomisation part F:*

In a factorial design, eligible patients may be randomised to the arms below. The dose listed is for adults; children <18 years old are excluded from this comparison.

- **No additional treatment**
- **Empagliflozin** 10 mg once daily for 28 days. [Introduced in protocol version 16.1; **enrolment ongoing**]

2.5.7 *Second randomisation for adults with progressive COVID-19*

Patients enrolled in the main RECOVERY trial and with clinical evidence of a hyper-inflammatory state may be considered for a second randomisation if they meet the following criteria:

- Randomised into the main RECOVERY trial no more than 21 days ago
- Clinical evidence of progressive COVID-19:
 - oxygen saturation <92% on room air or requiring oxygen; and

- C-reactive protein (CRP) ≥ 75 mg/L
- No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in this aspect of the RECOVERY trial

Eligible participants may be randomised between the following treatment arms:

- **No additional treatment**
- **Tocilizumab** by intravenous infusion with the dose determined by body weight. [Introduced in protocol version 4.0; **enrolment closed** 24 January 2021]

2.6 Definitions of primary and secondary outcomes

Outcomes will be assessed at 28 days and then 6 months after the relevant randomisation. Analysis of longer-term outcomes collected beyond this will be described in a separate Statistical Analysis Plan.

2.6.1 *Primary outcome*

Mortality (all-cause)

2.6.2 *Secondary clinical outcomes*

- Time to discharge from hospital
- Use of invasive mechanical ventilation (including Extra Corporal Membrane Oxygenation [ECMO]) or death (among patients not on invasive mechanical ventilation or ECMO at time of randomisation)

2.6.3 *Subsidiary clinical outcomes*

- Use of ventilation (overall and by type) among patients not on ventilation (of any type) at time of randomisation
- Duration of invasive mechanical ventilation among patients on invasive mechanical ventilation at time of randomisation (defined as time to successful cessation of invasive mechanical ventilation: see section 5.1.7)
- Use of renal dialysis or haemofiltration (among patients not on renal dialysis or haemofiltration at time of randomisation)
- Thrombotic events (overall and by type; introduced in Protocol version 10.1)

2.6.4 *Safety outcomes*

- Cause-specific mortality (COVID-19, other infection, cardiac, stroke, other vascular, cancer, other medical, external, unknown cause)
- Major cardiac arrhythmia (recorded on follow-up forms completed from 12 May 2020 onwards)
- Major bleeding (overall and by type; introduced in Protocol version 10.1)
- Early safety of antibody-based therapy (sudden worsening in respiratory status; severe allergic reaction; temperature $>39^{\circ}\text{C}$ or $\geq 2^{\circ}\text{C}$ rise since randomisation; sudden

hypotension; clinical haemolysis; and thrombotic events within the first 72 hours; Main randomization phase B only)

- Non-coronavirus infection (overall and by site and putative organism [virus, bacteria, fungus, other]; introduced in Protocol version 14.0)

2.6.5 *Detailed derivation of outcomes*

The detailed derivation of outcomes included in statistical analysis will be described separately in a data derivation document and included in the Study Data Reviewer's Guide.

2.7 Hypothesis framework

For each of the primary, secondary and subsidiary outcomes, the null hypothesis will be that there is no true difference in effect between any of the treatment arms.

2.8 Sample size

The larger the number randomised, the more accurate the results will be, but the numbers that can be randomised will depend critically on how large the epidemic becomes. If substantial numbers are hospitalised in the participating centres then it may be possible to randomise several thousand with moderate disease and a few thousand with severe disease. Some indicative sample sizes and projected recruitment will be estimated using emerging data for several different scenarios. Sample size and recruitment will be monitored by the TSC throughout the trial.

2.9 Randomisation

Eligible patients will be randomised using a 24/7 secure central web-based randomisation system, developed and hosted within NDPH, University of Oxford. Users of the system will have no insight into the next allocation, given that simple randomisation is being used. If a patient is randomised inadvertently more than once during the same hospital admission, the first allocation will be used.

The implementation of the randomisation procedure will be monitored by the Senior Trials Programmer, and the TSC notified if an error in the randomisation process is identified.

2.9.1 *Main randomisation part A*

Simple randomisation will be used to allocate participants to one of the following treatment arms (in addition to usual care), which is subject to change:

- No additional treatment
- Lopinavir-Ritonavir [Introduced in protocol version 1.0; **enrolment closed** 29 June 2020]
- Corticosteroid [Introduced in protocol version 1.0; **enrolment closed to adults** 8 June 2020]
- Hydroxychloroquine [Introduced in protocol version 2.0; **enrolment closed** 5 June 2020]
- Azithromycin [Introduced in protocol version 3.0; **enrolment closed** 27 November 2020]
- Colchicine [Introduced in protocol version 11.1; **enrolment closed** 5 March 2021]

- Dimethyl fumarate [Introduced in protocol version 14.0; **enrolment ongoing**]

The randomisation programme will allocated patients in a ratio of 2:1 between the no additional treatment arm and each of the other arms that are not contra-indicated and are available when multiple arms were included in the protocol. Hence if all 4 active treatment arms are available, then the randomisation will be in the ratio 2:1:1:1:1. If one or more of the active drug treatments is not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then this fact will be recorded via the web-based form prior to randomisation; random allocation will then be between the remaining arms (in a 2:1:1:1, 2:1:1 or 2:1 ratio). Since the closure of the azithromycin comparison, all comparisons in part A have used a 1:1 ratio.

2.9.2 *Main randomisation part B*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Convalescent plasma [Introduced in protocol version 6.0; **enrolment closed** 15 January 2021]
- Synthetic neutralising antibodies [Introduced in protocol version 9.1; **enrolment closed** 22 May 2021]

If the active treatment is not available at the hospital, the patient does not consent to receive convalescent plasma, or is believed, by the attending clinician, to be contraindicated for the specific patient, then this fact will be recorded via the web-based form and the patient will be excluded from the relevant arm in Randomisation part B.

2.9.3 *Main randomisation part C*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Aspirin [Introduced in protocol version 10.1; **enrolment closed** 21 March 2021]

2.9.4 *Main randomisation part D*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Baricitinib [Introduced in protocol version 13.0; **enrolment ongoing**]

2.9.5 *Main randomisation part E*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- High-dose corticosteroids [Introduced in protocol version 15.0; **enrolment ongoing**]

2.9.6 *Main randomisation part F*

In a factorial design, eligible patients will be randomised simultaneously using simple randomisation with allocation ratio 1:1 to one of the following arms, which is subject to change:

- No additional treatment
- Empagliflozin [Introduced in protocol version 16.1; **enrolment ongoing**]

Note: From protocol version 7.0 onwards, randomisation is permitted in part B of main randomisation without randomisation in part A. From protocol version 10.1 onwards, randomisation is permitted in any combination of parts A to F.

2.9.7 *Second randomisation for adults with progressive COVID-19*

Eligible participants will be randomised using simple randomisation with an allocation ratio 1:1 between the following arms, which is subject to change:

- No additional treatment
- Tocilizumab [Introduced in protocol version 4.0; **enrolment closed** 24 January 2021]

2.10 Blinding

This is an open-label study. However, while the study is in progress, access to tabular results of study outcomes by treatment allocation will not be available to the research team, CIs, trial statisticians, clinical teams, or members of the TSC (unless the DMC advises otherwise). The DMC and DMC statisticians will be unblinded.

2.11 Data collection schedule

Baseline and outcome information will be collected on trial-specific electronic case report forms (eCRFs) and entered into a web-based IT system by a member of the hospital or research staff. Follow-up information will be collected on all study participants, irrespective of whether they complete the scheduled course of allocated study treatment. Study staff will seek follow-up information through various means, including routine healthcare systems and registries.

All randomised participants will be followed up until death or 6 months post-randomisation to the main trial (whichever is sooner). NHS Digital and equivalent organisations in the devolved nations will supply data fields relevant to trial baseline and outcome measures to NDPH, University of Oxford on a regular basis, for participants enrolled into the trial. This will be combined with the trial-specific data collected via the web-based IT system and adjudicated internally.

Longer term (up to 10 years) follow-up will be sought through linkage to electronic healthcare records and medical databases including those held by NHS Digital, Public Health England and equivalent bodies, and to relevant research databases (e.g. UK Biobank, Genomics England).

2.12 Data monitoring

During the study all study data will be supplied in strict confidence to the independent DMC for independent assessment and evaluation. The DMC will request such analyses at a frequency relevant to the emerging data from this and other studies.

The DMC has been requested to determine if, in their view, the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. Hence, multiple reviews by the Data Monitoring Committee have no material impact on the final analysis. In such a circumstance, the DMC will inform the TSC who will make the results available to the public and amend the trial arms accordingly.

2.13 Trial reporting

The trial will be reported according to the principles of the CONSORT statements.^{2, 3, 4} The exact composition of the trial publication(s) depends on the size of the epidemic, the availability of drugs, and the findings from the various pairwise comparative analyses (with the no additional treatment arm) in the main trial.

3 ANALYSIS POPULATIONS

3.1 Population definitions

The intention to treat (ITT) population will be all participants randomised, irrespective of treatment received. This ITT population will be used for analysis of efficacy and safety data. For interim analyses, baseline data will be reported for all participants with data available and outcome data will be reported for all participants who have died, been discharged from hospital, or reached day 28 after the first randomisation.

4 DESCRIPTIVE ANALYSES

4.1 Participant throughput

The flow of participants through the trial will be summarised for each separate pairwise comparison using a CONSORT diagram. The flow diagram will show the contribution of participants from each of the paths (from each of the parts of the main randomisation and from the second randomisation), where applicable. The flow diagrams will describe the numbers of participants randomly allocated, who received allocation, withdrew consent, and included in the ITT analysis population. The flow diagrams for arms in the main randomisation will also report the number of participants who underwent the second randomisation.

4.2 Baseline comparability of randomised groups

The following characteristics will be described separately for patients randomised to each main comparison (for each separate pairwise comparison of active treatment with the no additional treatment arm), and separately for the first and second randomisation.

4.2.1 Main randomisation (parts A, B and C)

- Age at randomisation
- Sex
- Ethnicity
- Region (UK, non-UK)
- Time since COVID-19 symptoms onset
- Time since hospitalisation
- Current respiratory support
- Comorbidities (diabetes, heart disease, chronic lung disease, tuberculosis, human immunodeficiency virus, severe liver disease, severe kidney impairment)
- SARS-CoV-2 test result
- If female, known to be pregnant
- Use of systemic corticosteroid (including those allocated to corticosteroid in part A)
- Use of other relevant treatments (e.g. remdesivir, interleukin-6 antagonist, monoclonal anti-SARS-CoV-2 neutralising antibody)
- For part B only, anti-SARS-CoV-2 antibody concentration
- For treatment comparisons introduced in protocol v9.1 onwards:
 - C-reactive protein
 - Estimated glomerular filtration rate (calculated using the CKD-EPI formula)
 - D-dimer

4.2.2 Second randomisation

In addition to the above:

- Current respiratory support
- Latest oxygen saturation measurement
- Latest C-reactive protein
- Latest ferritin
- Latest estimated glomerular filtration rate (calculated using the CKD-EPI formula)
- Allocation in main randomisation parts A, B, C, D and E
- Interval between first and second randomisation

The number and percentage will be presented for binary and categorical variables. The mean and standard deviation or the median and the interquartile range will be presented for continuous variables.

4.3 Completeness of follow-up

All reasonable efforts will be taken to minimise loss to follow-up, which is expected to be minimal as data collection for primary and secondary outcomes using trial-specific eCRFs is combined with linkage to routine clinical data on study outcomes from NHS Digital, ICNARC, and similar organisations in the devolved nations.

The number and percentage of participants with follow-up information at day 28 and at 6 months after the relevant randomisation will be reported. Data will be shown for each of the following: all-cause mortality, hospital discharge status, ventilation status, and will be shown for each randomised group for the main and second randomisation separately.

4.4 Adherence to treatment

The number and proportion of patients who did not receive the treatment they were allocated to will be reported. If any other trial treatment options were known to be received, instead of or in addition to, the allocated treatment during the 28-day follow-up period after the first randomisation, these will be collected and reported. Details on the number of days (or doses) of treatment received will be reported for all trial treatments received where available.

5 COMPARATIVE ANALYSES

For all outcomes, the primary analysis will be performed on the intention to treat (ITT) population at 28 days after randomisation. (Additional details specific to the comparison of REGN-COV2 vs. usual care are provided in Appendix A. An ITT analysis of all outcomes at 6 months post-randomisation will also be conducted.

Pairwise comparisons will be made between each treatment arm and the no additional treatment arm (reference group) in that particular randomisation (main randomisation part A, main randomisation part B, main randomisation part C, main randomisation part D, main randomisation part E and second randomisation). Since not all treatments may be available or suitable for all patients, those in the no additional treatment arm will only be included in a given comparison if, at the point of their randomisation, they *could* alternatively have been randomised to the active treatment of interest (i.e. the active treatment was available at the time and it was not contra-indicated). The same applies to treatment arms added at a later stage; they will only be compared to those patients recruited concurrently.

5.1 Main randomisation part A

5.1.1 Primary outcome

Mortality (all-cause) will be summarised with counts and percentages by randomised comparison group. A time-to-event analysis will be conducted using the log-rank test, with the p-value reported. Kaplan-Meier estimates for the time to event will also be plotted (with associated log-rank p-values). The log-rank 'observed minus expected' statistic (and its variance) will be used to calculate the one-step estimate of the event rate ratio and confidence interval for each treatment group versus the no additional treatment group.⁵ For the primary outcome, discharge alive before the relevant time period (28 days after randomisation) will be assumed as absence of the event (unless there is additional data confirming otherwise).

5.1.2 Secondary outcomes

5.1.3 *Time to discharge alive from hospital*

A time-to-event analysis will be used to compare each treatment group with the no additional treatment group using the log-rank test. As described for the primary outcome, the rate ratio and its confidence interval will be estimated from the log-rank observed minus expected statistic and its variance, and Kaplan-Meier curves will be drawn. Patients who die in hospital will be censored after 28 days after randomisation. This gives an unbiased estimate of the recovery rate and comparable estimates to the competing risks approach in the absence of other censoring (which is expected to be very minimal).⁶

5.1.4 *Use of invasive mechanical ventilation (including ECMO) or death*

Counts and percentages will be presented by randomised group and the risk ratio will be calculated for each pairwise comparison with the no additional treatment arm, with confidence intervals and p-values reported. The absolute risk difference will also be presented with confidence intervals. Each component of this composite outcome will also be summarised. Patients who were already on invasive mechanical ventilation or ECMO at randomisation will be excluded from these analyses.

5.1.5 *Subsidiary clinical outcomes*

5.1.6 *Use of ventilation (overall and by type)*

Counts and percentages will be presented by randomised group for patients who received any assisted ventilation, together with risk ratios and confidence intervals for each pairwise comparison with the no additional treatment arm. The number of patients receiving the two main types of ventilation will also be reported: non-invasive ventilation (including CPAP, other non-invasive ventilation or high-flow nasal oxygen), and invasive mechanical ventilation (including ECMO). Patients who were already receiving ventilation^a at randomisation will be excluded from these analyses.

5.1.7 *Duration of invasive mechanical ventilation (time to successful cessation of invasive mechanical ventilation)*

Successful cessation of invasive mechanical ventilation will be defined as removal of invasive mechanical ventilation within (and survival to) 28 days after randomisation. A time-to-event analysis will be used to compare each treatment group with the no additional treatment group using the log-rank test, as described above. The rate ratio and its confidence interval will be estimated from the log-rank observed minus expected statistic and its variance, and Kaplan-Meier curves will be drawn. Patients who die within 28 days of randomisation will be censored *after* 28 days after randomisation. Patients who were not already on invasive mechanical ventilation or ECMO at randomisation will be excluded from these analyses.

5.1.8 *Use of renal dialysis or haemofiltration*

Counts and percentages will be presented by randomised group and the risk ratio will be calculated for each pairwise comparison with the no additional treatment arm, with

^a Participants recruited to the main randomisation prior to protocol version 9.1 who were already receiving oxygen at randomisation will also be excluded from these analyses (since it is not possible to distinguish those who were already receiving non-invasive ventilation).

confidence intervals and p-values reported. The absolute risk difference will also be presented with confidence intervals. Patients who were already on renal dialysis or haemofiltration at randomisation will be excluded from these analyses.

5.1.9 *Thrombotic event*

Counts and percentages will be presented by randomised group. The absolute risk differences will also be presented with confidence intervals. Type of thrombotic event will also be described: (i) acute pulmonary embolism; (ii) deep vein thrombosis; (iii) ischaemic stroke, (iv) myocardial infarction; (v) systemic arterial embolism; and (vi) all sites combined.

5.2 Main randomisation part B

In the factorial design, the main effects of treatments evaluated in part B will be presented and tested across all arms in main randomisation parts A, C, D, E and F combined, as described in 5.1. (Assessments of whether the effects of treatments in part B vary depending on other randomised treatments are described in section 5.10).

5.3 Main randomisation part C

In the factorial design, the main effects of treatments evaluated in part C will be presented and tested across all arms in main randomisation parts A, B, D, E and F combined, as described in 5.1. (Assessments of whether the effects of treatments in part C vary depending on other randomised treatments are described in section 5.10).

5.4 Main randomisation part D

In the factorial design, the main effects of treatments evaluated in part D will be presented and tested across all arms in main randomisation parts A, B, C, E and F combined, as described in 5.1. (Assessments of whether the effects of treatments in part D vary depending on other randomised treatments are described in section 5.10).

5.5 Main randomisation part E

In the factorial design, the main effects of treatments evaluated in part E will be presented and tested across all arms in main randomisation parts A, B, C, D and F combined, as described in 5.1. (Assessments of whether the effects of treatments in part E vary depending on other randomised treatments are described in section 5.10).

5.6 Main randomisation part F

In the factorial design, the main effects of treatments evaluated in part F will be presented and tested across all arms in main randomisation parts A to E combined, as described in 5.1. (Assessments of whether the effects of treatments in part F vary depending on other randomised treatments are described in section 5.10).

5.7 Second randomisation

Evaluation of treatment effects in the main randomisation and the second randomisation will be conducted independently, as described in 5.1.

5.8 Pre-specified subgroup analyses

Pre-specified subgroup analyses will be conducted for the main randomisation (parts A, B, C, D, E and F) and the second randomisation, for the following outcomes:

- Mortality (all-cause)
- Time to discharge from hospital
- Use of invasive mechanical ventilation (including ECMO) or death

Tests for heterogeneity (or tests for trend for 3 or more ordered groups) will be conducted to assess whether there is any good evidence that the effects in particular subgroups differ materially from the overall effect seen in all patients combined. Results will be presented on forest plots as event rate ratios, or risk ratios, with confidence intervals. The following subgroups will be examined based on information at randomisation:

- Age (<70; 70-79; 80+ years)
- Sex (Male; Female)
- Ethnicity (White; Black, Asian or Minority Ethnic)
- Region (UK, non-UK)
- Time since illness onset (≤ 7 days; > 7 days)
- Requirement for respiratory support
 - For main randomisation: None; Oxygen only; Non-invasive ventilation; Invasive mechanical ventilation (including ECMO)^b
 - For second randomisation: No ventilator support (including no or low-flow oxygen); Non-invasive ventilation (including CPAP, other non-invasive ventilation, or high-flow nasal oxygen), Invasive mechanical ventilation (including ECMO)
- Use of systemic corticosteroid (including dexamethasone)
- For part B only: Recipient anti-SARS-CoV-2 antibody concentration at randomisation ($< 8 \times 10^6$ units; $\geq 8 \times 10^6$ units^c). (This will be the key subgroup for the REGN-COV2 comparison.)

5.9 Sensitivity analyses

Sensitivity analyses of the primary and secondary outcomes will be conducted among those patients with a positive test for SARS-CoV-2 (i.e. confirmed cases).

5.10 Other exploratory analyses

In addition, exploratory analyses will be conducted to test for interactions between treatments allocated in each of the different randomisations, provided that doing so does not lead to premature unblinding of results for ongoing comparators.

^b Participants recruited before protocol V9.1 who were receiving oxygen would be presented in a fifth subgroup but not included in the test for trend

Non-randomised exploratory analyses will be used to explore the likely influence of different levels of convalescent plasma antibody concentrations on the efficacy of convalescent plasma.

Additional analyses will set the results for children (<18 years) and pregnant women in the context of the overall results.

5.11 Adjustment for baseline characteristics

The main analyses described above will be unadjusted for baseline characteristics. However, if there are any important imbalances between the randomised groups in key baseline pre-specified subgroups (see section 5.4) or allocation in the orthogonal components of the main randomisation, where applicable, emphasis will be placed on analyses that are adjusted for the relevant baseline characteristic(s). This will be done using Cox regression for the estimation of adjusted hazard ratios and a log-binomial regression model for the estimation of adjusted risk ratios.

5.12 Significance levels and adjustment of p-values for multiplicity

Evaluation of the primary trial (main randomisation) and secondary randomisation will be conducted independently, and no adjustment be made for these. Formal adjustment will not be made for multiple treatment comparisons, the testing of secondary and subsidiary outcomes, or subgroup analyses (with one exception; see Appendix A). However, due allowance for multiple testing will be made in the interpretation of the results: the larger the number of events on which a comparison is based and the more extreme the P-value after any allowance has been made for the nature of the particular comparison (i.e. primary or secondary; pre-specified or exploratory), the more reliable the comparison and, hence, the more definite any finding will be considered. 95% confidence intervals will be presented for the main comparisons.

5.13 Statistical software employed

The statistical software SAS version 9.4 and R Studio 3.6.2 (or later) for Windows will be used for the interim and final analyses.

5.14 Data standards and coding terminology

Datasets for analysis will be prepared using CDISC standards for SDTM and ADaM. Wherever possible, clinical outcomes (which may be obtained in a variety of standards, including ICD10 and OPCS-4) will be coded using MedDRA version 20.1.

6 SAFETY DATA

Suspected serious adverse reactions (SSARs) and suspected unexpected serious adverse reactions (SUSARs) will be listed by trial allocation.

For each of the following, counts and percentages will be presented by randomised group. Where possible, the absolute risk differences will also be presented with confidence intervals:

6.1 Cause-specific mortality

Cause-specific mortality (COVID-19, other infection, cardiac, stroke, other vascular, cancer, other medical, external, unknown cause) will be analysed in a similar manner to the primary outcome.

6.2 Major cardiac arrhythmia

Type of arrhythmia will also be described: (i) atrial flutter or fibrillation; (ii) supraventricular tachycardia; (iii) ventricular tachycardia; (iv) ventricular fibrillation; (v) atrioventricular block requiring intervention, with subtotals for (i)-(ii) and (iii)-(iv).

6.3 Major bleeding

Type of bleeding will also be described: (i) intracranial bleeding; (ii) gastro-intestinal bleeding; (iii) other bleeding site, and (iv) all sites combined.

6.4 Early safety of anti-coronavirus antibody-based therapy

Additional safety data will be collected in a subset of patients randomised to part B: (i) sudden worsening in respiratory status; (ii) severe allergic reaction; (iii) temperature $>39^{\circ}\text{C}$ or $\geq 2^{\circ}\text{C}$ rise since randomisation; (iv) sudden hypotension; (v) clinical haemolysis; and (vi) thrombotic event.

6.5 Other infections

Other infections occurring after randomisation will be described. These will be classified primarily by site (pneumonia, urinary tract, biliary, other intra-abdominal, blood stream, skin, other). Information on putative organism (other virus, bacterial, fungal, other and unknown) is also collected.

6.6 Metabolic complications

Incidence of the following metabolic complications after randomisation will be described:

- Ketoacidosis (defined as combination of ketosis [blood ketones ≥ 1.5 mmol/L or urine ketones $\geq 2+$] and acidosis [venous bicarbonate < 15 mmol/L])
- Hyperglycaemic hyperosmolar state
- Other hyperglycaemia requiring new use of insulin
- Severe hypoglycaemia (causing reduced conscious level requiring another person to help recover)

7 ADDITIONAL POST-HOC EXPLORATORY ANALYSIS

Any post-hoc analysis requested by the oversight committees, a journal editor or referees will be labelled explicitly as such. Any further future analyses not specified in the analysis protocol will be exploratory in nature and will be documented in a separate statistical analysis plan.

8 DIFFERENCES FROM PROTOCOL

The testing of multiple treatment arms will not formally be adjusted for, but given the number of comparisons, due allowance will be made in their interpretation. Formal methods of adjustment for multiplicity were not adopted because of treatment arms being added over time (including the factorial convalescent plasma comparison), unequal recruitment into each arm, and the ultimate number of treatments under evaluation not being known in advance.

This analysis plan will be updated prior to unblinding of the 6-month follow-up results. Additional analyses may be specified, e.g. to explore the impact of randomised treatment allocation on hospital re-admission for COVID-19.

9 EARLY PHASE ASSESSMENTS

The following approach is required for the evaluation of treatments indicated as undergoing Early Phase Assessment in the protocol (introduced in Protocol version 14.0):

9.1 Definitions of clinical outcomes

9.1.1 *Primary outcome*

- WHO ordinal scale on day 5

9.1.2 *Secondary clinical outcomes*

- Time to sustained (ie, value better than baseline value persisting for >1 day) improvement by at least one category on the WHO ordinal scale from baseline
- S/F₉₄ ratio at day 3 and 5
- Time to discharge from hospital
- Improvement in clinical status at day 10
- Study average blood C-reactive protein

9.1.3 *Subsidiary clinical outcomes*

- All other subsidiary outcomes as described above (section 2.6.3)

9.1.4 *Safety outcomes*

- Flushing (incidence, severity)
- Gastrointestinal symptoms (incidence, severity)
- Reasons for stopping study treatment
- Transaminitis (ALT >3x upper limit of normal)
- Acute kidney injury (creatinine >1.5x value entered at randomisation)
- All other subsidiary outcomes as described above (section 2.6.4)

9.2 Baseline comparability of randomised groups

Unless otherwise specified, analyses will follow the plan described above (section 4). In addition, the following characteristics will be described:

- Oxygen saturation measurement on air (if available)
- S/F₉₄ ratio
- WHO Ordinal Scale
- All other characteristics as described above (section 4.2)

9.3 Comparative analysis

Unless otherwise specified, comparative analyses will follow the plan described above (section 5). In addition,

9.3.1 *Primary outcome*

The primary comparison will involve an “intention to treat” analysis among all participants randomised between the active arm and its control of the effect of the active treatment on WHO scale at day 5, adjusted for baseline.

9.3.2 *Secondary outcomes*

9.3.2.1 Time to sustained improvement by at least one category on the WHO ordinal scale from baseline

A time-to-event analysis will be used to compare each treatment group with the no additional treatment group using the log-rank test. The rate ratio and its confidence interval will be estimated from the log-rank observed minus expected statistic and its variance, and Kaplan-Meier curves will be drawn. Patients who die in hospital will be censored 28 days after randomisation.

9.3.2.2 Improvement in clinical status at day 10

Counts and percentages will be presented by randomised group for patients with an improvement of at least one category on the WHO ordinal scale from baseline, together with odds ratios and confidence intervals for each pairwise comparison with the no additional treatment arm.

9.3.2.3 Study average blood C-reactive protein

Median and standard deviation of study average C-reactive protein will be presented by randomised group for patients, together with p-value for each pairwise comparison with the no additional treatment arm.

9.3.2.4 S/F₉₄ ratio at days 3 and 5

Mean and standard deviation of S/F₉₄ ratio on days 3 and 5 (adjusted for baseline) will be presented by randomised group for patients, together with p-value for each pairwise comparison with the no additional treatment arm.

9.3.3 Safety outcomes

Counts and percentages will be presented by randomised group. The absolute risk differences will also be presented with confidence intervals for each of the following:

- Flushing (incidence, severity)
- Gastrointestinal symptoms (incidence, severity)
- Reasons for stopping study treatment
- Transaminitis (ALT >3x upper limit of normal)
- Acute kidney injury (creatinine >1.5x value entered at randomisation)

10 6-MONTH ASSESSMENTS

This section details the proposed analysis of the clinical outcomes 6 months after initial randomisation in the RECOVERY trial.

10.1 Trial outcomes

Unless otherwise specified, primary, secondary, subsidiary, and safety outcomes are as specified earlier in this document. Subgroup analyses will be conducted in the same subgroups as used in the 28 day outcome publications.

10.1.1 *Changes to definition of clinical outcomes*

10.1.1.1 *Use of ventilation*

For the secondary and subsidiary clinical outcomes, use of ventilation includes ventilation occurring during index admission, or where the participant is readmitted. (Elective admissions will be excluded since ventilation recorded during such admissions are likely to be related to elective surgery rather than complications of COVID-19.)

10.1.1.2 *Use of renal dialysis or haemofiltration*

Use of renal dialysis or haemofiltration at any point during the 6 months following randomisation is included.

10.1.2 *Additional exploratory analyses*

10.1.2.1 *Hospital recorded diagnoses*

For UK participants, diagnoses recorded in hospital datasets after randomisation are identified where they are the primary diagnoses relating to a period in inpatient care. These diagnoses are classified according to whether they are recorded during a planned or emergency (including transfers) admission.

Diagnoses will be tabulated by the categories defined for analysis of cause specific mortality (see below and section 2.6.4). Additional subcategories will be considered (see table below) with any categories containing a small number of events (e.g. fewer than 10) combined with other relevant categories.

Table: Sub-categories of hospital recorded diagnosis considered

COVID-19		
Other infection	Skin soft tissue	Bacterial/fungal/viral/TB/other/unspecified
	Abdominal	Bacterial/fungal/viral/TB/other/unspecified
	Respiratory	Bacterial/fungal/viral/TB/other/unspecified
	Bone and joint	Bacterial/fungal/viral/TB/other/unspecified
	Urinary	Bacterial/fungal/viral/TB/other/unspecified
	Bloodstream	Bacterial/fungal/viral/TB/other/unspecified
	Other	Bacterial/fungal/viral/TB/other/unspecified
	Unspecified	Bacterial/fungal/viral/TB/other/unspecified

Cardiovascular	Cardiac Stroke Other vascular	MI/other CHD/Heart failure/other cardiac Haemorrhagic/ischaemic/unknown Arterial thrombo-embolism/venous thromboembolism/other vascular
Other	Cancer Diabetes Extra-cranial bleed or perforation Liver Renal Respiratory (not infection) Other medical cause	GI/other
External		
Unknown		

The start date for each diagnosis extracted from the hospitalisation dataset will be used for time-to-event analyses.

Data on admissions to hospital after randomisation will be collected in a complementary way for participants outside the UK.

10.1.2.2 Total duration of critical and hospital in-patient care

In order to assess the total burden of care for the participant and the health system, the following will be extracted from the routine healthcare data and presented as mean (SD) duration in days:

- Total duration (in days) of hospital in-patient care during the 6 months after randomisation
- Total duration (in days) of critical care during the 6 months after randomisation
- Total number of admissions categorised by planned vs emergency (including transfers)

10.2 Censoring and analysis

For the 6 month analyses, participants will be censored at the earliest of death, withdrawal of consent or on study day 184 (where day of randomisation is study day 1).

By 6 months, nearly all participants have either died or been discharged alive, allowing the full effects of the trial treatments on the index admission (i.e. the admission in which the participant was randomised) to be assessed.

11 REFERENCES

11.1 Trial documents

Study protocol, case report forms, training materials, and statistical analysis plan are published on the trial website.

11.2 Other references

1. Gamble C, Krishan A, Stocken D, Lewis S, Juszcak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA* 2017;318(23):2337-2343.
2. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:698-702.
3. Juszcak E, Altman DG, Hopewell S, Schulz KF. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. *JAMA* 2019;321(16):1610-1620.
4. Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. *BMJ*. 2020 Jun 17;369:m115. doi: 10.1136/bmj.m115. PMID: 32554564; PMCID: PMC7298567.
5. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II: analysis and examples. *Br J Cancer* 1977;35:1-39.
6. Betensky RA and Schoenfeld DA. Nonparametric Estimation in a Cure Model with Random Cure Times. *Biometrics* 2001;57:282-286.
7. The National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis* 2020; 20: 1390-1400

12 APPENDIX A: ANALYSES OF REGN-COV2

12.1 Background & rationale

The RECOVERY trial is testing multiple interventions in a broad population of patients hospitalised with COVID-19. The protocol and statistical analysis plan outline the methods that are to be used in the analysis of these interventions and, to date, the same approach has been appropriate for all completed comparisons. However, it is important that the statistical analysis plan be informed by the best available information about the treatment being tested¹ and the pathophysiology of the disease.

Relevant new information about the effects of REGN-COV2 have emerged since it was added to the trial in September 2020.

REGN-COV2 is a mixture of two synthetic monoclonal antibodies which bind to the receptor binding domain of the SARS-CoV-2 spike protein and neutralise the virus.² Recently-published trials of REGN-COV2 in ambulatory patients (i.e. those recently diagnosed in the community) have demonstrated that it has larger effects on viral load among people who are “seronegative” at the time of randomisation (i.e. they do not have detectable antibodies of their own against SARS-CoV-2), and seropositive patients derive little or no benefit (in terms of reduction in viral load) from REGN-COV2, compared to placebo.³ Participant serostatus therefore is a potentially key modifier of the effect of REGN-COV2 that may be observed in RECOVERY.

All participants entering the REGN-COV2 comparison in RECOVERY are asked to provide a serum sample which is sent to a central laboratory at the University of Oxford, where antibodies against SARS-CoV-2 are measured using a validated assay. Previous assessments of this assay alongside commercially available assays shows excellent performance at discriminating prior SARS-CoV-2 infection with sensitivity and specificity above 98%.⁴

Earlier versions of the statistical analysis plan recognised the importance of the seronegative subgroup, but review of the emerging literature and regulatory guidance⁵ has led to a change in approach to these analyses. The revised analysis plan for the REGN-COV2 comparison explicitly tests the hypothesis that any benefit of REGN-COV2 on the primary outcome may be wholly or largely restricted to patients who are seronegative at the time of randomisation with little or no benefit among those who are seropositive at that point.

For the avoidance of doubt, all decisions about this modification to the analytical plan were made before recruitment was complete and before any members of the trial steering committee (who are responsible for drafting and approving the SAP) or investigators had access to any unblinded analyses of clinical outcome data for the REGN-COV2 comparison. No members of the independent Data Monitoring Committee (who are the only individuals who can review interim unblinded analyses) were involved in this change.

12.2 Analytical plan

The primary outcome and secondary outcomes remain unchanged. For each outcome, rate ratios and 95% confidence intervals will be calculated separately for participants who are seronegative, seropositive, or with unknown status as well as for the whole trial population. A test for heterogeneity between seronegative and seropositive participants will be presented. The results will be interpreted based on the totality of the evidence.

For the purposes of any regulatory submission: Because any beneficial effect of REGN-COV2 is hypothesised to be larger among seronegative participants (and may be negligible in seropositive participants), the primary outcome will first be assessed among participants who are known to be seronegative at randomisation. If the null hypothesis is rejected in the seronegative group at 2-tailed $p=0.05$, then the primary outcome will be assessed among the whole population (i.e. seronegative, seropositive, and those with unknown status combined). Otherwise, no further hypothesis testing will be performed.

A similar approach will be taken for each of the two pre-specified secondary outcomes (discharge alive within 28 days and, among patients not on invasive mechanical ventilation at baseline, the use of invasive mechanical ventilation or death) if both primary hypotheses are rejected. Hypothesis testing will first be conducted among the participants who are known to be seronegative at randomisation and, if the null hypothesis is rejected at 2-tailed $p=0.025$, then will be assessed among the whole population (see Table).

Table: Hierarchical Testing Order

Hierarchy Number	Type of Outcome	Outcome	Analysis Population	Significance level, α (2-sided)
1.	Primary	Mortality (all-cause), 28 days after randomisation	Seronegative at randomisation	0.05
2.	Primary	Mortality (all-cause), 28 days after randomisation	All participants randomised	0.05
3.*	Secondary	Time to discharge alive from hospital, within 28 days after randomisation	Seronegative at randomisation	0.025
4.	Secondary	Time to discharge alive from hospital, within 28 days after randomisation	All participants randomised	0.025
3.*	Secondary	Use of invasive mechanical ventilation (including ECMO) or death	Seronegative and not on invasive mechanical ventilation at randomisation	0.025
4.	Secondary	Use of invasive mechanical ventilation (including ECMO) or death	All participants randomised not on invasive mechanical ventilation at randomisation	0.025

* These will be performed simultaneously. Testing will only proceed to the respective overall population if the null hypothesis is rejected in the seronegative group at the specified level of statistical significance.

12.3 References

- Food and Drug Administration. E9 Statistical Principles for Clinical Trials. 1998.
- Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 2020;369:1010-4.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med* 2021;384:238-51.

4. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis* 2020;20:1390-400.
5. Food and Drug Administration. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products - guidance for industry. 2019.

13 APPROVAL

Trial Statistician	Name: Mr Enti Spata	
	Signature:	Date:
Chief Investigator	Name: Professor Peter Horby	
	Signature:	Date:
Deputy Chief Investigator	Name: Professor Martin Landray	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Edmund Juszcak	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Alan Montgomery	
	Signature:	Date:
Steering Committee Statistician	Name: Professor Thomas Jaki	
	Signature:	Date:

14 DOCUMENT HISTORY

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
0.1	20/03/20	LL/JB	First draft.	Prior	Prior
0.2	01/04/20	LL/JB	Comments and amendments from Martin Landray, Jonathan Emberson & Natalie Staplin. Also aligned with updated protocol and CRFs.	Prior	Prior
0.3	01/04/20	EJ/LL	Further edits and comments.	Prior	Prior
0.4	07/04/20	JB/EJ/LL	Following statistics group meeting on 02/04/20.	Prior	Prior
0.5	22/04/20	JB/LL/EJ	Following statistics group meeting on 09/04/20 and further protocol update.	After	Prior
0.6	24/04/20	LL	Following statistics group meeting on 23/04/20.	After	Prior
0.7	10/05/20	LL	Protocol update.	After	Prior
0.8	15/05/20	LL	Following statistics group meeting on 15/05/20.	After	Prior
0.9	27/05/20	LL	Further comments from TSC members prior to interim analysis on 28/05/20.	After	Prior
1.0	09/06/20	LL	Revised following the stopping of the hydroxychloroquine arm, and prior to the trial statisticians receiving unblinded data for this arm.	After	Prior
1.1	21/06/20	LL/JB/RH	Additional clarification of ventilation denominators. Adjustment for any imbalances of subgroup characteristics between treatment arms at randomisation. Clarification of analysis of composite outcome. Removal of 'Unknown' ethnicity subgroup. Addition of section 5.5 Adjustment for baseline characteristics.	After	After unblinding of hydroxychloroquine and dexamethasone arms.

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
2.0	04/11/20	EJ/ES	Revised to reflect changes in protocol, including introduction of factorial randomisations and new arms, including convalescent plasma, tocilizumab, synthetic neutralizing antibodies (REGN-COV2, and aspirin.	Prior to interim analysis of aspirin arm After interim analyses of all other arms	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, and dexamethasone arms. Prior to unblinding of any other arms
2.1	02/12/20	ES	Addition of colchicine. Modification of definition of recipient antibody concentration subgroup.	Prior to interim analyses including antibody results or of colchicine arm.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, and dexamethasone arms. Prior to unblinding of any other arms
2.2	27/01/21	ES	Clarification of non-invasive ventilation-related subgroups. Addition of baricitinib.	Prior to interim analyses of baricitinib arm.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, azithromycin and dexamethasone arms (and primary outcome in overall population in convalescent plasma arm). Prior to unblinding of any other arms

Version	Date	Edited by	Comments/Justification	Timing in relation to unblinded interim monitoring	Timing in relation to unblinding of Trial Statisticians
3.0	15/05/21	ES	Specification of method for REGN-COV2 comparison (appendix A). Addition of early phase assessment of dimethyl fumarate. Addition of infliximab and high-dose corticosteroids.	Prior to interim analyses of infliximab or high-dose steroids.	After unblinding of 28-day results for hydroxychloroquine, lopinavir-ritonavir, azithromycin, dexamethasone, colchicine and convalescent plasma arms. Prior to unblinding of any other arms.
3.1	29/10/21	RH	Modification of early phase assessments to align with protocol V18.1 Modification of 6 months analysis section.	Prior to early phase assessments or 6 month analyses.	Prior to unblinding of dimethyl fumarate or 6 month outcome data.